Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.
DOI: 10.17615/74ry-7003
Authors: Grohe, Christian, Baldini, Editta, Souquet, Pierre-Jean, Dy, Grace K, Lopez-Chavez, Ariel, Cappuzzo, Federico, Mazières, Julien, Lena, Hervé, Levy, Benjamin P, Planchard, David, Mennecier, Bertrand, Ramalingam, Suresh S, Baudelet, Christine, Rizvi, Naiyer A, Wolf, Jürgen, Dowlati, Afshin, Huber, Rudolf M, Sanborn, Rachel, Otterson, Gregory A, Stinchcombe, Thomas E, Minenza, Elisa, Lestini, Brian J, Gandara, David R, Antonia, Scott J, Zalcman, Gérard, Horn, Leora, Campos, Luis T, Nair, Suresh G, Chouaid, Christos, Harbison, Christopher T
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4298239141